SAGE Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of central nervous system (CNS) disorders. The company was founded in 2010 by Steven Paul, Jeff Jonas, and Doug Covey, with its headquarters in Cambridge, Massachusetts, USA.
SAGE Therapeutics specializes in creating therapies that target specific receptors in the brain to address neurological and psychiatric conditions. Their research and development efforts are primarily centered around understanding the role of the GABA and NMDA receptors in various CNS disorders, such as depression, postpartum depression, essential tremor, and others.
One of SAGE Therapeutics' significant achievements was the development of the drug brexanolone, also known by its brand name Zulresso. In March 2019, the U.S. Food and Drug Administration (FDA) approved Zulresso as the first and only treatment specifically for postpartum depression. This approval marked a groundbreaking advancement in the field of maternal mental health.
SAGE Therapeutics is listed on the NASDAQ stock exchange under the ticker symbol "SAGE." It has gained recognition and attention from investors and researchers for its innovative approach to CNS disorders and its potential to offer new treatment options for patients with unmet medical needs.